S&P 500   3,968.53 (+0.88%)
DOW   33,833.29 (+0.70%)
QQQ   283.37 (+1.01%)
AAPL   142.30 (+0.96%)
MSFT   247.35 (+1.22%)
META   115.14 (+1.06%)
GOOGL   94.25 (-0.73%)
AMZN   89.74 (+1.45%)
TSLA   172.47 (-0.90%)
NVDA   168.23 (+4.36%)
NIO   13.37 (+6.28%)
BABA   93.72 (+6.10%)
AMD   69.82 (-0.46%)
T   19.11 (-0.98%)
MU   55.51 (+3.14%)
CGC   3.14 (-3.09%)
F   13.11 (+0.08%)
GE   82.95 (-2.41%)
DIS   92.55 (+0.43%)
AMC   6.13 (+1.32%)
PYPL   74.40 (-0.03%)
PFE   51.40 (+2.31%)
NFLX   309.17 (+0.24%)
S&P 500   3,968.53 (+0.88%)
DOW   33,833.29 (+0.70%)
QQQ   283.37 (+1.01%)
AAPL   142.30 (+0.96%)
MSFT   247.35 (+1.22%)
META   115.14 (+1.06%)
GOOGL   94.25 (-0.73%)
AMZN   89.74 (+1.45%)
TSLA   172.47 (-0.90%)
NVDA   168.23 (+4.36%)
NIO   13.37 (+6.28%)
BABA   93.72 (+6.10%)
AMD   69.82 (-0.46%)
T   19.11 (-0.98%)
MU   55.51 (+3.14%)
CGC   3.14 (-3.09%)
F   13.11 (+0.08%)
GE   82.95 (-2.41%)
DIS   92.55 (+0.43%)
AMC   6.13 (+1.32%)
PYPL   74.40 (-0.03%)
PFE   51.40 (+2.31%)
NFLX   309.17 (+0.24%)
S&P 500   3,968.53 (+0.88%)
DOW   33,833.29 (+0.70%)
QQQ   283.37 (+1.01%)
AAPL   142.30 (+0.96%)
MSFT   247.35 (+1.22%)
META   115.14 (+1.06%)
GOOGL   94.25 (-0.73%)
AMZN   89.74 (+1.45%)
TSLA   172.47 (-0.90%)
NVDA   168.23 (+4.36%)
NIO   13.37 (+6.28%)
BABA   93.72 (+6.10%)
AMD   69.82 (-0.46%)
T   19.11 (-0.98%)
MU   55.51 (+3.14%)
CGC   3.14 (-3.09%)
F   13.11 (+0.08%)
GE   82.95 (-2.41%)
DIS   92.55 (+0.43%)
AMC   6.13 (+1.32%)
PYPL   74.40 (-0.03%)
PFE   51.40 (+2.31%)
NFLX   309.17 (+0.24%)
S&P 500   3,968.53 (+0.88%)
DOW   33,833.29 (+0.70%)
QQQ   283.37 (+1.01%)
AAPL   142.30 (+0.96%)
MSFT   247.35 (+1.22%)
META   115.14 (+1.06%)
GOOGL   94.25 (-0.73%)
AMZN   89.74 (+1.45%)
TSLA   172.47 (-0.90%)
NVDA   168.23 (+4.36%)
NIO   13.37 (+6.28%)
BABA   93.72 (+6.10%)
AMD   69.82 (-0.46%)
T   19.11 (-0.98%)
MU   55.51 (+3.14%)
CGC   3.14 (-3.09%)
F   13.11 (+0.08%)
GE   82.95 (-2.41%)
DIS   92.55 (+0.43%)
AMC   6.13 (+1.32%)
PYPL   74.40 (-0.03%)
PFE   51.40 (+2.31%)
NFLX   309.17 (+0.24%)
NASDAQ:MGNX

MacroGenics - MGNX Stock Forecast, Price & News

$6.20
+0.16 (+2.65%)
(As of 12/8/2022 01:20 PM ET)
Add
Compare
Today's Range
$5.95
$6.29
50-Day Range
$3.34
$6.98
52-Week Range
$2.13
$17.94
Volume
12,364 shs
Average Volume
1.18 million shs
Market Capitalization
$381.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.89

MacroGenics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
78.5% Upside
$10.89 Price Target
Short Interest
Healthy
7.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
-0.10mentions of MacroGenics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$4.66 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.48) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

250th out of 1,027 stocks

Pharmaceutical Preparations Industry

109th out of 503 stocks

MGNX stock logo

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

Why Shares of MacroGenics Were Dropping Tuesday
Why MacroGenics Stock Crushed the Market on Monday
MacroGenics (MGNX) Q3 2022 Earnings Call Transcript
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Company Calendar

Last Earnings
11/02/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
427
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.89
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+75.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

Net Income
$-202,120,000.00
Net Margins
-204.95%
Pretax Margin
-204.95%

Debt

Sales & Book Value

Annual Sales
$77.45 million
Book Value
$3.91 per share

Miscellaneous

Free Float
56,618,000
Market Cap
$381.11 million
Optionable
Optionable
Beta
2.11

Key Executives

  • Dr. Scott Koenig M.D. (Age 70)
    Ph.D., Pres, CEO & Director
    Comp: $954.14k
  • Mr. James  KarrelsMr. James Karrels (Age 55)
    Sr. VP, CFO & Corp. Sec.
    Comp: $577.9k
  • Mr. Eric Blasius Risser (Age 49)
    Chief Operating Officer
    Comp: $571.98k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 55)
    Sr. VP of Technical Operations
    Comp: $550.97k
  • Dr. Ezio Bonvini (Age 68)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Dr. Christopher Shayne James M.D.
    VP of Investor Relations & Corp. Communications
  • Mr. Jeffrey Stuart Peters (Age 50)
    Sr. VP & Gen. Counsel
  • Dr. Stephen L. Eck M.D. (Age 67)
    Ph.D., Sr. VP of Clinical Devel. & Chief Medical Officer
  • Ms. Lynn Cilinski (Age 64)
    VP, Controller & Treasurer













MGNX Stock - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price forecast for 2023?

10 Wall Street analysts have issued 12-month target prices for MacroGenics' shares. Their MGNX share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $10.89 in the next year. This suggests a possible upside of 78.5% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2022?

MacroGenics' stock was trading at $16.05 at the start of the year. Since then, MGNX shares have decreased by 62.0% and is now trading at $6.10.
View the best growth stocks for 2022 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.23. The biopharmaceutical company had revenue of $15.66 million for the quarter, compared to analyst estimates of $39.56 million. MacroGenics had a negative trailing twelve-month return on equity of 111.57% and a negative net margin of 204.95%. During the same period in the previous year, the business earned ($0.66) earnings per share.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.31%), Vanguard Group Inc. (6.80%), Assenagon Asset Management S.A. (2.93%), Federated Hermes Inc. (2.29%), State Street Corp (2.24%) and Two Sigma Advisers LP (1.54%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $6.10.

How much money does MacroGenics make?

MacroGenics (NASDAQ:MGNX) has a market capitalization of $374.97 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does MacroGenics have?

The company employs 427 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 12/8/2022 by MarketBeat.com Staff